Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort

Osteoporosis International

Volumn 24, Issue 3, 2013, Pages 1045-1055

  Sanfelix Genoves J ^a,b   Sanfelix Gimeno G ^a   Peiro S ^a   Hurtado, I ^a   Fluixa C ^b   Fuertes, A ^c   Campos, J C ^c   Giner, V ^d   Baixauli, C ^a  

^a Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Centro de Salud Nazaret   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Cross sectional; Osteoporosis; Osteoporotic fracture; Risk assessment; Risk factors

Indexed keywords

ALENDRONIC ACID; CALCIUM; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; ANTHROPOMETRY; ARTICLE; CALCIUM INTAKE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DENSITOMETRY; DIAGNOSTIC TEST; ELECTRONIC MEDICAL RECORD; FALLS EFFICACY SCALE; FAMILY HISTORY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEDENTARY LIFESTYLE; SMOKING; SPAIN; VITAMIN SUPPLEMENTATION;

ACCIDENTAL FALLS; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM, DIETARY; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PREVALENCE; RECURRENCE; RISK FACTORS; SEDENTARY LIFESTYLE; SMOKING; SPAIN;

EID: 84878875315     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2018-6     Document Type: Article

References (45)

1. Sanfélix-Genovés J, Reig-Molla B, Sanfélix-Gimeno G, Peiró S, Graells-Ferrer M, Vega-Martínez M et al (2010) The population-based prevalence of osteoporotic vertebral fracture and densitometric osteoporosis in postmenopausal women over 50 in Valencia, Spain (the FRAVO study). Bone 47(3):610-616
2. Sanfélix-Genovés J, Hurtado I, Sanfélix-Gimeno G, Reig-Molla B, Peiró S (2011) Impact of osteoporosis and vertebral fractures on quality-of-life. A population-based study in Valencia, Spain (the FRAVO study). Health Qual Life Outcomes 6:9-20
3. Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14(5):383-388
4. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4(6):368-381
5. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK (2008) Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149(6):404-415
6. National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. [Available at: http://www.nof.org/]
7. Management of osteoporosis in postmenopausal women (2010) Position statement of (2010) The North American Menopause Society. Menopause 17(1):25-54
8. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF et al (2010) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(Suppl 3):1-37
9. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254-1259
10. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285(6):785-795
11. Kanis JA, on behalf of the World Health Organisation Scientific Group (2007) Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. [Available at http://www.shef.ac.uk/FRAX/pdfs/WHO-Technical-Report.pdf ]. Accessed 15 January 2011.
12. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:b4229. doi: 10.1136/bmj.b4229
13. van den Bergh JP, van Geel TA, Lems WF, Geusens PP (2010) Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep 8(3):131-137
14. Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD et al (2007) Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA 298(20):2389-2398
15. Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA et al (2011) FRAX(®) position development conference members. J Clin Densitom 14(3):171-180
16. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033-1046
17. González-Macías J, Marín F, Vila J, Díez-Pérez A, Abizanda M, Alvarez R et al (2004) Risk factors for osteoporosis and osteoporotic fractures in a series of 5,195 women older than 65 years. Med Clin (Barc) 123(3):85-89
18. Vila J, Marín F, González-Macías J, Martín D, Tojeiro S, Díez-Pérez A, representación de los investigadores del proyecto ECOSAP (2009) Validation of an algorithm to calculate the absolute risk of non-vertebral fragility fractures in a cohort of postmenopausal women. Med Clin (Barc) 133(13):501-505
19. Sanfélix-Genovés J, Peiró S, Sanfélix-Gimeno G, Giner V, Gil V, Pascual M et al (2010) Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study. BMC Publ Health 10:153
20. Azagra R, Roca G, Encabo G, Prieto D, Aguyé A, Zwart M et al (2011) Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain. BMC Musculoskelet Disord 12:30
21. Tebé C, Espallargues M, Estrada MD, Kotzeva A, del Río LM, Di Gregorio S (2011) Validación del modelo predictivo de fractura osteoporótica FRAX. Ministerio de Ciencia e Innovación. Agència d'Informació, Avaluació i Qualitat en Salut, Madrid
22. González-Macías J, Marin F, Vila J, Díez- Pérez A (2012) Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort. Bone 50(1):373-377
23. Sanfélix-Genovés J, Peiró S, Sanfélix-Gimeno G, Hurtado I, Pascual de la Torre M, Trillo-Mata JL et al (2010) Impact of a multifaceted intervention to improve the clinical management of osteoporosis. The ESOSVAL-F study. BMC Health Serv Res 10:292
24. Sanfélix-Gimeno G, Sanfélix-Genovés J, Peiró S, Hurtado I, Trillo JL, Usó R et al (2011) Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia region (Spain). The ESOSVAL-AD study. BMC Musculoskelet Disord 12:178
25. Spanish Health Survey. Encuesta Nacional de Salud 2009. Available at http://www.ine.es/metodologia/t15/t1530419cues06.htm. Accessed 15 January 2012
26. Carretero Baeza ML, Gómez Vazquez M, coord (1995) Tablas de Composición de Alimentos Españoles. Madrid: Ministerio de Sanidad y Consumo
27. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385-397
28. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864-1873
29. Anuari Estadístic Comunitat Valenciana (2006) Valencia: Institut Valencià d'Estadística; 2007
30. Arana-Arri E, Gutiérrez-Ibarluzea I, Ecenarro Mugaguren A, Asua Batarrita J (2007) Prevalence of certain osteoporosis-determining habits among post menopausal women in the Basque Country, Spain, in 2003. Rev Esp Salud Publica 81(6):647-656
31. Luz Rentero M, Carbonell C, Casillas M, González Béjar M, Berenguer R (2008) Risk factors for osteoporosis and fractures in postmenopausal women between 50 and 65 years of age in a primary care setting in Spain: a questionnaire. Open Rheumatol J 2:58-63
32. Roig Vilaseca D, Gómez Vaquero C, Hoces Otero C, Nolla JM (2010) Fracture risk calculated with the FRAX index in patients with osteoporosis treated and untreated. Med Clin (Barc) 134(5):189-193
33. Azagra Ledesma R, Prieto-Alhambra D, Encabo Duró G, Casado Burgos E, Aguyé Batista A, Díez-Pérez A, grupo de estudio FRIDEX (2011) Usefulness of FRAX tool for the management of osteoporosis in the Spanish female population. Med Clin (Barc) 136(14):613-619
34. Del Río BL, Tebé Cordomi C, Johansson H, Di Gregorio MS, Estrada Sabadell D, Espallargues Carreras M (2011) Evaluación del riesgo absoluto de fractura mediante herramienta FRAX® en una cohorte española. Rev Osteoporos Metab Miner 3(2):85-93
35. Tebé C, del Río LM, Casas L, Estrada MD, Kotzeva A, Di Gregorio S, Espallargues M (2011) Risk factors for fragility fractures in a cohort of Spanish women. Gac Sanit 25(6):507-512
36. de Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T (2010) Clinical characteristics of patients under treatment for osteoporosis in a primary care centre. Who do we treat? Aten Primaria 42(11):559-563
37. Albrand G, Munoz F, Sornay-Rendu E, DuBoeuf F, Delmas PD (2003) Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32(1):78-85
38. Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O (2001) An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12(7):519-528
39. McGrother CW, Donaldson MM, Clayton D, Abrams KR, Clarke M (2002) Evaluation of a hip fracture risk score for assessing elderly women: the Melton osteoporotic fracture (MOF) study. Osteoporos Int 13(1):89-96
40. Warensjö E, Byberg L, Melhus H, Gedeborg R, Mallmin H, Wolk A et al (2011) Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 342:d1473
41. Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA et al (2011) Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 22(3):817-827
42. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis J et al (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25(11):2350-2358
43. Couris CM, Chapurlat RD, Kanis JA, Johansson H, Burlet N, Delmas PD et al (2011) FRAX(®) probabilities and risk of major osteoporotic fracture in France. Osteoporos Int. doi: 10.1007/s00198-011-1883-8
44. Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC et al (2010) Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 25(7):1506-1511
45. Trémollieres F, Cochet T, Cohade C, Pouillès JM, Ribot C (2010) Fracture risk in early postmenopausal women assessed using FRAX. Joint Bone Spine 77(4):345-348